Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.09 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $28.3 million versus the consensus estimate of $28.84 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.